- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03762200
SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
A Prospective, Clinical Study Evaluating the Safety and Haemostatic Effectiveness of SURGICEL® Powder, in Mild or Moderate Parenchymal or Soft Tissue Bleeding During General, Gynaecological, Urological, and Cardiothoracic Surgery
This is a prospective, single arm, multicentre, multispecialty, post market, clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis (control bleeding) when conventional methods of control are impractical or ineffective during surgery (open, laparoscopic or thoracoscopic) in adult subjects (18 years or older).
After application of SURGICEL Powder, the Target Bleeding Site (TBS) will be assessed for haemostasis (no detectable bleeding) at 3, 5, and 10 minutes from application and prior to initiation of closure.
All enrolled subjects will be followed post-operatively through discharge and again at 30 days and 6 months post-surgery via phone call or office visit.
Study Overview
Detailed Description
This is an open label, prospective, single arm, multicentre, multispecialty, post-marketing clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis in the control of capillary, venous, and small arterial haemorrhage when ligation or other conventional methods of control are impractical or ineffective during surgery (open, laparoscopic or thoracoscopic) in adult subjects (18 years or older). Prospective subjects will be informed about the nature of the research, given the informed consent form (ICF) to read, and, if he/she understands the content, will be asked to provide consent by signing the ICF.
Screening and enrolment will continue until at least 100 evaluable subjects from approximately eight (8) investigational sites, with an appropriate mild or moderate Target Bleeding Site (TBS) are included into the study. The TBS will be the only region evaluated for the primary endpoint and all secondary effectiveness endpoints.
All enrolled subjects will be followed post-operatively through discharge, and via phone call or office visit at 30 days (+14 days) post-surgery. In addition, all enrolled subjects will receive a 6-month (+/-30 days) follow-up phone call or office visit to assess the occurrence of any serious adverse event (SAE) requiring surgical intervention and assessed as possibly related or related to the study treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Genk, Belgium, 3600
- Ziekenhuis Oost Limburg
-
Gent, Belgium, 9000
- Universitair Ziekenhuis Gent
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Cambridge University Hospitals NHS Trust (Addenbrooke's Hospital)
-
Clydebank, United Kingdom, G81 4DY, GB
- Golden Jubilee National Hospital
-
Leeds, United Kingdom, LS9 7TF
- Leeds Teaching Hospitals NHS Trust (St James's University Hospital)
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
- Newcastle upon Tyne NHS Foundation Trust (Freeman Hospital)
-
Nottingham, United Kingdom, NG7 2UH
- Nottingham University Hospitals NHS Trust
-
-
Lothian
-
Edinburgh, Lothian, United Kingdom, EH4 2XU
- NHS Lothian (Western General Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pre-operative:
- Adult subjects ≥ 18 years requiring elective/non-emergent open or laparoscopic general, gynaecological, cardiothoracic, or urological surgical procedures;
- Subject or authorised representative has signed the approved Informed Consent;
Subject(s) whose International Normalised Ratio is <1.5 within 24 hours of surgery.
Intra-operative:
- Presence of an appropriate TBS identified intra-operatively by the surgeon;
- Subject(s) undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to TBS identification and treatment.
Exclusion Criteria:
Pre-operative:
- Female subjects who are pregnant or nursing;
Subject on anticoagulation medication (with exception of aspirin) prior to surgery. Washout periods for respective medications must be observed.
If information is not readily available within the Instructions for Use (IFU), a conservative approach should be taken and intravenous heparin stopped 12 hours prior to surgery and 2 days prior for oral medication;
- Subject on antiplatelet/P2Y12 inhibitors medication prior to surgery. Platelet recovery times for respective medication must be observed. If information is not readily available within the IFU, a conservative approach should be taken and medication stopped 5 days prior to surgery.
- Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor;
- Subjects who are known, current alcohol and/or drug abusers;
Subjects with any pre-operative findings identified by the surgeon that may preclude conduct of the study procedure.
Intra-operative:
- Subjects with any intra-operative findings identified by the surgeon that may preclude the use of study product;
- Subject with TBS in an actively infected field [Class III Contaminated or Class IV Dirty or Infected (see Appendix 2 in in Section 15.2)];
- TBS is on arteries or veins where application of SURGICEL Powder would present a risk of introducing the study product into an open blood vessel;
- Major arterial or venous bleeding or major defects in arteries and veins;
- TBS where silver nitrate or any other escharotic chemicals have been applied;
- TBS is in, around, or in proximity to foramina in bone, or areas of bony confine, the spinal cord, or optic nerve and chiasm;
- TBS in urological procedures where plugging (blocking) of the urethra, ureter or a catheter is possible by the study product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: SURGICEL Powder - Single arm
Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
|
SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Haemostatic Success at 5 Minutes
Time Frame: From application of SURGICEL Powder to 5 minutes after application
|
Proportion of subjects achieving haemostatic success at 5 minutes following application of SURGICEL Powder with no rebleeding requiring additional treatment at the Target Bleeding Site (TBS) any time prior to initiation of final fascial closure
|
From application of SURGICEL Powder to 5 minutes after application
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Haemostatic Success at 3 Minutes
Time Frame: From application of SURGICEL Powder to 3 minutes after application
|
Proportion of subjects achieving haemostatic success at 3 minutes following application of SURGICEL Powder with no rebleeding requiring additional treatment at the TBS any time prior to initiation of final fascial closure
|
From application of SURGICEL Powder to 3 minutes after application
|
Haemostatic Success at 10 Minutes
Time Frame: From application of SURGICEL Powder to 10 minutes after application
|
Proportion of subjects achieving haemostatic success at 10 minutes following the application of SURGICEL Powder with no rebleeding that requires additional treatment at the TBS any time prior to initiation of final fascial closure
|
From application of SURGICEL Powder to 10 minutes after application
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing a Thromboembolic Event
Time Frame: From application of SURGICEL Powder to 30 day follow-up visit
|
Number of participants experiencing a thromboembolic event that was assessed as having either an unlikely, possible, probable or causal relationship to the study treatment
|
From application of SURGICEL Powder to 30 day follow-up visit
|
Number of Participants With Post-operative Re-bleeding
Time Frame: From initiation of final fascial closure to the 30-day follow up visit
|
Number of participants of post-operative re-bleeding that was assessed as having either an unlikely, possible, probable or causal relationship to the TBS and requiring medical/surgical intervention
|
From initiation of final fascial closure to the 30-day follow up visit
|
Number of Participants Experiencing a Serious Adverse Events Requiring Surgical Intervention and Related to SURGICEL Powder
Time Frame: From time of SURGICEL Powder application to 6-month follow up visit
|
Number of participants experiencing a serious adverse event requiring surgical intervention and assessed as having either an unlikely, possible, probable or causal relationship to the study treatment
|
From time of SURGICEL Powder application to 6-month follow up visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIOS-2017-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhage
-
Al Hadi HospitalCompletedDiabetic Vitreous HemorrhageKuwait
-
Region StockholmRecruitingRetinal Hemorrhage, Bilateral | Retinal Hemorrhage, Left Eye | Retinal Hemorrhage, Right EyeSweden
-
Massachusetts Eye and Ear InfirmaryCompletedPost-operative HemorrhageUnited States
-
Panhandle Eye Group, LLPRecruitingDiabetic Vitreous HemorrhageMexico
-
Weill Medical College of Cornell UniversityThe Edward Grayson Fund for Retinal ResearchUnknownSubretinal Hemorrhage and Exudative MaculopathyUnited States
-
Ain Shams Maternity HospitalUnknownPost Operative HemorrhageEgypt
-
Tel-Aviv Sourasky Medical CenterIsrael Defense ForcesRecruiting
-
Assistance Publique - Hôpitaux de ParisTerminatedHemorrhage; Complicating DeliveryFrance
-
University of Sao PauloUnknownHemorrhage | RecurrentBrazil
-
University of PisaCompletedPost Operative HemorrhageItaly
Clinical Trials on SURGICEL Powder
-
Ethicon, LLCCompleted
-
Soonchunhyang University HospitalUnknownNon-variceal Upper Gastrointestinal BleedingKorea, Republic of
-
National Taiwan University HospitalUnknownPancreatic FistulaTaiwan
-
Cairo UniversityUnknownEndometrial HyperplasiaEgypt
-
Catholic University of the Sacred HeartCompleted
-
GATT Technologies BVRecruitingLiver Diseases | Gallbladder Diseases | Intraoperative Bleeding | Hemorrhage, SurgicalUnited States
-
Soonchunhyang University HospitalCompletedMalignant Neoplasm of Stomach | Benign Neoplasm of StomachKorea, Republic of
-
Aesculap AGCompletedPeripheral Vascular Diseases | HemostasisGermany
-
Tel-Aviv Sourasky Medical CenterUnknownThyroid Diseases | Goiter | Thyroid NoduleIsrael